Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1996 1
2001 2
2002 3
2003 8
2004 6
2005 15
2006 14
2007 12
2008 7
2009 13
2010 12
2011 16
2012 14
2013 19
2014 15
2015 12
2016 10
2017 7
2018 9
2019 9
2020 3
2021 3
2022 2
2023 3
2024 0

Text availability

Article attribute

Article type

Publication date

Similar articles for PMID: 16925730

191 results

Results by year

Filters applied: . Clear all
Page 1
Development of HIV-1 drug resistance through 144 weeks in antiretroviral-naïve subjects on emtricitabine, tenofovir disoproxil fumarate, and efavirenz compared with lamivudine/zidovudine and efavirenz in study GS-01-934.
Margot NA, Enejosa J, Cheng AK, Miller MD, McColl DJ; Study 934 Team. Margot NA, et al. J Acquir Immune Defic Syndr. 2009 Oct 1;52(2):209-21. doi: 10.1097/QAI.0b013e3181b05f7c. J Acquir Immune Defic Syndr. 2009. PMID: 19644384 Clinical Trial.
Tenofovir disoproxil fumarate, emtricitabine, and efavirenz versus fixed-dose zidovudine/lamivudine and efavirenz in antiretroviral-naive patients: virologic, immunologic, and morphologic changes--a 96-week analysis.
Pozniak AL, Gallant JE, DeJesus E, Arribas JR, Gazzard B, Campo RE, Chen SS, McColl D, Enejosa J, Toole JJ, Cheng AK. Pozniak AL, et al. J Acquir Immune Defic Syndr. 2006 Dec 15;43(5):535-40. doi: 10.1097/01.qai.0000245886.51262.67. J Acquir Immune Defic Syndr. 2006. PMID: 17057609 Clinical Trial.
The emergence of drug resistant HIV variants at virological failure of HAART combinations containing efavirenz, tenofovir and lamivudine or emtricitabine within the UK Collaborative HIV Cohort.
Bulteel N, Bansi-Matharu L, Churchill D, Dunn D, Bibby D, Hill T, Sabin C, Nelson M; UK Collaborative HIV Cohort (CHIC) Study Group; UK HIV Drug Resistance Database (UK HDRD) Study Group. Bulteel N, et al. J Infect. 2014 Jan;68(1):77-84. doi: 10.1016/j.jinf.2013.09.005. Epub 2013 Sep 20. J Infect. 2014. PMID: 24055802
A randomized comparison of second-line lopinavir/ritonavir monotherapy versus tenofovir/lamivudine/lopinavir/ritonavir in patients failing NNRTI regimens: the HIV STAR study.
Bunupuradah T, Chetchotisakd P, Ananworanich J, Munsakul W, Jirajariyavej S, Kantipong P, Prasithsirikul W, Sungkanuparph S, Bowonwatanuwong C, Klinbuayaem V, Kerr SJ, Sophonphan J, Bhakeecheep S, Hirschel B, Ruxrungtham K; HIV STAR Study Group. Bunupuradah T, et al. Antivir Ther. 2012;17(7):1351-61. doi: 10.3851/IMP2443. Epub 2012 Jul 2. Antivir Ther. 2012. PMID: 23075703 Clinical Trial.
191 results